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Reaction of 2-(2-(2-azidoethoxy)ethoxy)ethyl 6-O-(prop-2-ynyl)-b-D-galactopyranoside (7) under CuAAC
conditions gives rise to mixed cyclic and linear triazole-linked oligomers, with individual compounds up
to d.p. 5 isolable, along with mixed larger oligomers. The linear compounds resolve en bloc from the
cyclic materials by RP HPLC, but are separable by gel permeation chromatography. The triazole-linked
oligomersdpseudo-galactooligomersdwere demonstrated to be acceptor substrates for the multi-copy
cell surface trans-sialidase of the human parasite Trypanosoma cruzi. In addition, these multivalent
TcTS ligands were able to block macrophage invasion by T. cruzi.
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The blood-borne protozoan parasite Trypanosoma cruzi causes
Chagas’ disease, a debilitating and often lethal condition that af-
ﬂicts millions of people in South and Central America. There is
a desperate need for new treatments for this disease, with a re-
quirement for the identiﬁcation of new drug targets and potential
therapeutic agents.1e3 The biology of carbohydratesdglycobiology4
dpresents many underexplored targets and opportunities5,6 for
drug discovery.7 Including T. cruzi8 makes extensive use of cell
surface mucin glycoproteins9 and associated enzyme activities,
trans-sialidases, in its’ attempt to evade the human immune re-
sponse of one hand, and to adhere to and invade host cells on the
other.10,11 T. cruzi trans-sialidase (TcTS) is considered a relevant drugail address: rob.ﬁeld@jic.ac.uk
r Ltd. This is an open access articltarget for Chagas’ disease.12,13 With this in mind, we have in-
vestigated glycopeptide substrates for and inhibitors of TcTS,14,15
including the application of CuAAC click chemistry16 with carbo-
hydrate building blocks17e19 to access libraries of small molecule
inhibitors20e22 and multivalent TcTS ligands displayed on calixar-
ene cores.23
There is much current interest in the use of multivalent glyco-
conjugates as anti-pathogen agents18,24,25 and click chemistry
presents interesting opportunities for the generation of oligomeric
triazole-linked structures.26,27,27b CuAAC click chemistry has found
application in the synthesis of analogues of cyclic oligosaccharides,27
with medium size macrocycles being prepared in moderate to good
yields starting both from protected28,29 and ‘free’ sugar de-
rivatives.30,31 There are only a few examples of the successful oli-
gomerisation/polymerisation of such azide-alkyne-functionalised
carbohydrates leading to linear oligomers, including recent
proximity-driven click-polymerization of an 4-O-propargyl-b-D-
galactopyranosyl azide in a crystal lattice32,33 and click-
polymerisation of an open chain azido-alkyne derivative ofe under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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oligomerisation of azido-alkyne-functionalised sugars gives rise to
relatively rigid 1,6-linked cyclic pseudo-galactooligosaccharides that
are recognised by TcTS.31 In the present study, we wished to access
linear oligomers and/or largermacrocycles, in order to spana greater
area that might more adequately map to the distribution of trans-
sialidase on the parasite cell surface, so blocking trans-sialidase-
action and associated infection processes35 (Fig. 1). Here we have
designed linkers between sugar and azide functionality, in contrast
to our previous work. We opted for ethylene glycol-based linkers to
reduce the potential for non-speciﬁc interactions with proteins and
membrane components.36We anticipated that these ﬂexible linkers
might also promote oligomerisation at the expense of cyclisation.
Here we report the chemical synthesis of azido-alkyne-
functionalised galactose monomer 7, CuAAC click reactions thereof
and characterisation of the resulting triazole-linked oligomers. Fi-
nally, assessment of the interaction of these triazole-linked mate-
rials with TcTS is reported, along with initial assessment of their
ability to block macrophage invasion by T. cruzi parasites.Fig. 1. Schematic representation of cell surface-presented Trypanosoma cruzi trans-
sialidase and potential for its’ inhibition by 1,2,3-triazole-linked linear and cyclic
pseudo-galactooligomers.
Scheme 1. Synthetic route to azido-alkyne-containing galactose monomer 7. Reagents
and conditions: a) BzCl, Py, 81%; b) NH3, MeOH/THF (7:3), 64%; c) Cl3CCN, DBU, CH2Cl2,
85%; d) 2-(2-(2-chloroethoxy)ethoxy)ethanol, TMSOTf, CH2Cl2, 85%; e) NaN3, NaI, DMF,
97%; f) NaOMe, MeOH, 92%.2. Results and discussion
2.1. Synthesis of azido-alkyne galactose-containing monomer
The azido-alkyne-substituted galactose monomer 7 was syn-
thesised in nine steps starting from known 6-O-propargyl-D-gal-
actopyranose 1,31 as outlined in Scheme 1. Propargyl ether 1 was
per-O-benzyolated and converted into the required hemiacetal 3
using a solution of ammonia in methanol-THF. The resulting
hemiacetal 3 was treated with trichloroacetonitrile and DBU to
obtain the corresponding imidate donor 4, which upon activation
with trimethylsilyl triﬂuoromethanesulfonate (TMSOTf) in the
presence of 2-(2-(2-chloroethoxy)ethoxy)ethanol gave chlorinatedb-glycoside 5 in a respectable 85% yield for the glycosylation step.
In the presence of NaN3 and NaI, the chlorinated b-galactoside 5
was converted into the azido b-galactoside 6 in near quantitative
yield.The presence of azide functionality in 6 was evident from
a characteristic signal in the IR spectrum [2107 cm1] and the b-
conﬁguration followed from the anomeric proton signal (d 5.75,
J1,2¼8.0 Hz) in the 1H NMR spectrum. De-O-benzoylation of 6
afforded target azido-alkyne-functionalised galactose monomer 7
in an overall yield of 25% from 6-O-propargyl galactopyranose 1.37
2.2. Cyclisation and oligomerisation through CuAAC reactions
based on azido-alkyne-containing galactose monomer 7
Once synthesised, the reactivity of azido-alkyne-functionalised
galactose monomer 7 was tested under CuAAC conditionsdat
1 M concentration in DMF with CuSO4/Cu turnings either at 110 C
(using microwave irradiation; Method A) or at ambient tempera-
ture (Method B). The progress of both reactions could conveniently
be followed by TLC analysis. The reaction using Method A was
complete after 30 min, compared to 2 days for Method B. TLC
analysis showed formation of multiple common products, consis-
tent with the intended oligomerisation, while different relative
spot intensities were evident from the two methods (Fig. 2, TLC
lanes A and B). The reaction mixtures from both methods were
concentrated under reduced pressure, redissolved in water and
submitted to reverse phase (RP) HPLC puriﬁcation. This allowed
straightforward separation of cyclic from linear products, as well as
resolution of the variously sized cyclic oligomers from each other
(Fig. 2, HPLC traces A and B) resulting in samples of cyclic monomer
8, cyclic dimer 9, cyclic trimer 10, cyclic tetramer 11, cyclic pen-
tamer 12 and cyclic hexamer 13, alongwithmixed linear oligomers,
which interestingly did not resolve under the reverse phase HPLC
conditions employed to separate the corresponding cyclic materials
(Scheme 2). The formation of cyclic 1,4-triazole-linked structures
was conﬁrmed by virtue of singlet signals of triazole CH protons at
d 8.10 ppm38 and the absence of propargyl CH signals at d 2.83 in 1H
NMR spectra.
Fig. 2. Reverse phase HPLC and normal phase TLC analyses of cyclic and linear products obtained from 1,3 azido-alkyne cycloaddition reactions of monomer 7 (1M in DMF). HPLC
trace/TLC lane: A, Method A (Cu(I), 110 C); B, Method B (Cu(I), room temperature); C, Method C (110 C); D, Method D (room temperature); TLC lane 7, starting monomer 7; TLC lane
L, puriﬁed mixed linear oligomer fraction.
Scheme 2. Cyclisation and oligomerisation of monomer 7 (1M in DMF), through CuAAC employing Method A (Cu(I), 110 C) and Method B (Cu(I), room temperature). Yields (%) for
Method A and Method B.
V.L. Campo et al. / Tetrahedron 71 (2015) 7344e73537346The linear oligomeric products eluted on reverse phase HPLC as
a single broad peak at ca. 32 min (Fig. 2, HPLC traces A and B). These
compounds were well resolved from each other and from the cor-
responding cyclic oligomers on analytical TLC (Fig. 2, lane L), linearoligomers 14e18 have slightly higher Rf values compared to cyclic
product of the same molecular size. Monomer 7 was shown to un-
dergo oligomerisation up to at least a decamer. These analyses
alongside isolated yields (see Figs. 2 and 3 and Table S1 in
Fig. 3. Linear oligomerisation products from the reaction of monomer 7 under CuAAC conditions identiﬁed by HRMS compounds 14e18 were obtained in a combined yield of 26%
(Method A) and 36% (Method B).
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ature (room temperature vs 110 C) favours formation of linear
productsover the correspondingcyclic isomers. In contrast to reverse
phase HPLC, gel permeation chromatography (GPC) on TSK-HW40S
enabled separation of linear oligomers up to the pentamer (Fig. 3).
It should be noted that these linear compounds contain unreacted
azido and alkyne terminal groups capable of further reactions even in
the absence of Cu(I) catalyst. This gave rise to complications during
handling and storage due to spontaneous cyclisation and oligomer-
isation of puriﬁed compounds (data not shown).
The 1,3-dipolar cycloaddition of azido-alkyne galactosemonomer
7 generates series of isomeric cyclic and linear products that have the
same molecular formula and hence the same monoisotopic mass.39
This was conﬁrmed by high resolution MS analyses of individual
isolated cyclic compounds 8e13 as well as the mixture of linear
oligomers collected as a single peak inHPLC puriﬁcation (Fig. 2, HPLC
traces A and B; TLC lane L). Cyclic and linear products from trimer
upwards run inMS analyses as multiply charged species, spectra for,
which were de-convoluted to obtain monoisotopic masses (Table 1).Table 1
HRMS data of 1,4-triazole-linked cyclic products and linear oligomers
Calculated
m/z [MþH]þ
Cyclic
compounds
Found
m/z [MþH]þ
Linear
oligomers
Founda
m/z [MþH]þ
Monomer 376.1751 8 376.1701 7 376.1708
Dimer 751.3357 9 751.3334 14 751.3351
Trimer 1126.4998 10 1126.4961 15 1126.4985
Tetramer 1501.6640 11 1501.6511 16 1501.6631
Pentamer 1876.8281 12 1876.8248 17 1876.8273
Hexamer 2251.9923 13 2251.9792 18 2251.9897
a Data obtained from the analysis of the mixture of linear oligomers obtained as
a result of reverse-phase HPLC puriﬁcation.Cyclic oligomers had distinctive appearances in 1H NMR spectra: for
centrosymmetric macrocyles 8e13 these were represented by rela-
tively simple spectra of the repeat unit compared to more complex
spectra, as be expected for linear oligomers 14e18.
2.3. Uncatalysed 1,3-dipolar cycloaddition of azido-alkyne-
containing galactose monomer 7
Given the noted spontaneous but slow 1,3-dipolar cycloaddition
of monomer 7 on standing at room temperature (vide supra), the
reactivity of 7 at 1 M concentration in DMF at 110 C (under mi-
crowave irradiation; Method C) and at room temperature (Method
D) were compared (Scheme 3). Reaction using Method C was
complete after 30 min, while Method D gave approximately 10%
conversion of monomer 7 after two weeks. TLC analysis showed
even more complex multiple product mixtures than the Cu(I)-
catalysed reaction (Fig. 2, TLC lanes C and D) due to the expected
formation of mixed isomeric 1,4- and 1,5-linked triazoles.
The reaction mixture from Method C was concentrated under
reduced pressure, redissolved in water and submitted to the re-
verse phase HPLC puriﬁcation. This procedure again allowed sep-
aration of cyclic from linear products, as well as resolution of 1,4-
and 1,5-linked isomeric cyclic triazole monomer structures 8 and
19 from each other (Fig. 2, HPLC Trace C). Cyclic oligomers eluted on
RP HPLC as mixtures of poorly resolved regioisomers, with various
combinations of 1,4- and 1,5-linked triazole rings incorporated into
macrocycle structures. The ring sizes of mixed 1,4/1,5-linked cyclic
dimers (C2), mixed 1,4/1,5-linked cyclic trimers (C3), mixed 1,4/1,5-
linked cyclic tetramers (C4), mixed 1,4/1,5-linked cyclic pentamers
(C5) and mixed 1,4/1,5-linked cyclic hexamer (C6) were established
by mass spectrometry.
Scheme 3. Spontaneous cyclisation and oligomerisation of monomer 7 leading to a mixture of compounds incorporating both 1,4-linked and 1,5-linked 1,2,3-triazole residues.
V.L. Campo et al. / Tetrahedron 71 (2015) 7344e73537348The 1,5-linked cyclic monomer 19 was fully characterised by
NMR spectroscopy and HRMS. The formation of the 1,5-linked tri-
azole unit was conﬁrmed by observing the triazole CH singlet signal
at d 7.71 and the absence of a propargyl CH signal at d 2.83 in the 1H
NMR spectra. The 1,4/1,5-linked mixed linear products were sub-
mitted to GPC puriﬁcation on TSK-HW40S in water, which enabled
separation of mixed linear products up to a tetramer where linear
1,5-linked triazole dimer 20 and linear 1,4-linked dimer 14, isolable
as single compounds, were characterised by NMR spectroscopy and
mass spectrometry.
The linear structures of dimers 14 and 20 were conﬁrmed by
NMR spectroscopy, in particular by observation of a methylene
signal of the intact propargyl group at d w4.18 in the 1H NMR
spectra. In addition, DTT reduction of azido group in 20 produced
amino-terminated compound, which was detected by MS analy-
sis showing an [MþH]þ peak at m/z 725.28, compared to unre-
duced precursor with an [MþH]þ peak at m/z 751.33. The triazole
linkage type in 14 and 20 was also evident from the 1H NMR
spectra, which showed diagnostic proton resonances of 1,4-Scheme 4. Proposed sialylated products structures 21, 22 and 23 of enzymatic transformatio
trans-sialidase in 100 mM, pH 7.5 phosphate buffer, 28 C, 9 days.linked triazoles at d 8.04 for 14 and of 1,5-linked triazoles at
d 7.80 for 20.38
2.4. Cyclic triazole-linked oligomers as acceptor substrates
for Trypanosoma cruzi trans-sialidase (TcTS)
Cyclic compounds 8e10 and 19 were tested for their ability to
act as substrates for TcTS,21,40 with fetuin serving as a donor
substrate for O-3 sialylation of the galactose residues in the
triazole-linked macrocycles. Reactions were carried out over the
course of 9 days, with addition of further fetuin and enzyme after 5
days, and addition of fetuin again after 7 days. The reaction mix-
tures were monitored by TLC and in all cases formation of new
compounds was observed, which were identiﬁed by HRMS. Thus,
reaction of 1,4 triazole-linked cyclic trimer 10 resulted in forma-
tion of mono-, di- and tri-sialylated products 21, 22 and 23, re-
spectively (Scheme 4). Related reactivity was observed for 1,4-
triazole-linked cyclic dimer 9, which gave two sialylated prod-
ucts, mono-sialylated and di-sialylated derivatives. The 1,4-n of compound 10. Reagents and conditions: 3 mM fetuin, 1 mM compound 10, T. cruzi
V.L. Campo et al. / Tetrahedron 71 (2015) 7344e7353 7349triazole-linked cyclic monomer 8 and 1,5-triazole-linked cyclic
monomer 19 gave mono-sialylated products as expected (see
Supplementary data). It is therefore evident that cyclic triazole-
linked pseudo-galactooligomers are recognised by, and can act as
acceptor substrates for, TcTS.
2.5. Preliminary biological evaluation of triazole-linked
oligomers
As the trans-sialidase is an important enzyme associated
with host cell invasion by T. cruzi,11,35 we evaluated the bi-
ological potential of our triazole-linked oligomers as blockers of
parasite mammalian cell entry. The trypomastigote form of theFig. 4. Inhibition of T. cruzi invasion of bovine macrophages in the presence of 1,4/1,5-triazole-linked cyclic dimers (C2), trimer (C3), tetramer (C4), pentamer (C5), hexamer (C6),
heptamer (C7) and a series of mixed 1,4/1,5-triazole-linked linear oligomers. A: Parasites were applied to macrophages without ( ) or with ( ) pre-incubation with triazoles and
following 6 days incubation the numbers of trypomastigotes in the medium was quantiﬁed as % reduction in the number of parasite released from macrophages (% inhibition). B:
Parasites and triazoles were applied to macrophages and the number of amastigotes present inside the macrophages was quantiﬁed as an average number of parasite per mac-
rophage (T. cruzi/Macrophage).parasite invades mammalian cells, where it differentiates into
amastigote forms that replicate and subsequently de-
differentiate to tryposmatigotes. The latter then exit the cell in
search of other cells to infect. Our assays were therefore two-
fold: assessment of the number of trypomastigotes present in
the medium, or assessment of the number of amastigotes inside
macrophages.Fig. 5. Representative images illustrating amastigote-form parasite numbers present inside macrophages infected with T. cruzi in (A) the absence and (B) the presence of 250 mM
mixed length 1,4/1,5 triazole-linked linear oligomers. Arrows indicate cells infected with T. cruzi.Parasites were mixed with bovine macrophages and triazole-
linked oligomers, with or without a pre-incubation of the parasite
and oligomers; where a pre-incubation was employed, free triazole-linked oligomers were removed by washing before adding the para-
sites to macrophages. The parasites were left to invade the macro-
phagesandafter6days, thetrypomastigote formfound inthemedium
was removed and counted. As shown in Fig. 4 A ( ), the incubation of
parasite with triazole-linked oligomers substantially inhibited the
invasion of macrophage by parasites (>90% for trimer-hexamer). To
rule out a direct impact of the triazole-linked compounds on the
macrophages, pre-incubationof parasiteswith triazoles, pluswashing
to remove excess triazole, was assessed.While the impact on parasite
invasion was more modest than when the triazole was present
throughout (Fig. 4 A ), this is to be expected given the dramatic re-
duction in concentration of the inhibitor in these experiments. Grat-
ifyingly, inhibition of macrophage invasionwas still pronounced.To complement the above assays, we also assessed differenti-
ated amastigote-form Trypanosoma cruzi numbers inside infected
macrophages, and the impact of triazole-linked oligomers on these
numbers. In keeping with the trypomastigote results (Fig. 4 A),
triazole-linked oligomers resulted in a reduction in the number of
parasites found inside macrophages (Fig. 4 B; Fig. 5), with a general
trend towards larger structures giving greater effect.Taken together, these data conﬁrm the potential of triazole-
linked trans-sialidase ligands to block macrophage invasion by T.
cruzi parasites.
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In this study we have investigated the CuAAC-mediated oligo-
merisation of an azido-alkyne-functionalised galactose building
block 7 for the development of novel oligomeric, triazole-linked
compounds with potential for impact against the human parasite
Trypanosoma cruzi. Despite our initial expectation that the in-
stallation of ﬂexible ethylene-glycol-based linker might favour
polymerisation of monomer over cyclisation, mixed populations of
linear and cyclic triazole-linked oligomers of d.p. 1 to >10 were
evident. The cyclic compounds were separable from each other and
from the corresponding linear materials by RP HPLC, whilst sepa-
ration of linear materials up to d.p. 5 could be achieved by gel
permeation chromatography. The overall yield of triazole-linked
products obtained from polymerisation/cyclooligomerisation of
monomer 7 was around 54%, with a higher proportion of linear
products (36%) compared to cyclic products (18%) formed in CuAAC
reactions conducted at room temperature.
Judicious choice of the sites of galactose modiﬁcation in
monomer 7 (the 1- and 6-positions) results in oligomeric triazole-
linked materials that present the 2-, 3- and 4-hydroxyl groups of
the sugar units that are required for binding to T. cruzi trans-siali-
dase.40 This was borne out by in vitro biotransformations, which
established that triazole-linked 1,6-substituted pseudo-gal-
actoligomers are indeed recognised as acceptor substrates by T.
cruzi trans-sialidase. Given the high copy number presentation of
trans-sialidase on the surface of T. cruzi, multivalent ligands for the
enzyme might block the surface of the parasite and inhibit TcTS-
mediated host cell invasion. Encouragingly, preliminary assess-
ment of linear and cyclic triazole-linked pseudo-galactooligomers
clearly establishes their ability to block T. cruzi invasion of macro-
phages, with distinct advantage demonstrated by pre-incubation of
triazole-linked oligomers with parasite prior to exposure to mac-
rophages. While this phenomenon would be difﬁcult to reproduce
medicinally, it suggests that there is scope for optimisation of li-
gand presentation. The versatile nature of CuAAC-based oligo-
merisation approach offers signiﬁcant scope in this regard.
4. Experimental section
Chemicals were purchased as reagent grade and used without
further puriﬁcation. Ammonia solution (7N NH3 in methanol) and
methanolic sodium methoxide (0.5M NaOMe in methanol) were
purchased from Sigma Aldrich. All moisture-sensitive reactions
were performed under a dry nitrogen atmosphere using oven-dried
glassware. Anhydrous solvents were purchased from Sigma Aldrich
and dichloromethane was freshly distilled from CaH2 prior to use.
Microwave-assisted reactions were carried out in Biotage Initiator
microwave. Reactions were monitored by thin-layer chromatogra-
phy (TLC) on aluminium-backed, pre-coated silica gel plates (Silica
Gel 60 F254, E. Merck) with the indicated eluents. Compounds were
visualised under UV light (l 254 nm) and by dipping in ethanol-
sulfuric acid (95:5, v/v) followed by heating. Flash chromatogra-
phy was performed on a Biotage Isolera MPLC system using pre-
packed silica gel cartridges. HPLC was carried out using a Dionex
system equipped with a Corona Charged Aerosol (CAD) detector.
Gel permeation chromatography was performed on a TSK-HW40S
column (1.680 cm) eluted with water at 0.4 mL/min ﬂow rate.
Optical rotations were measured at 20 C in 1 mL cell in the stated
solvent using a PerkineElmer 341 polarimeter equipped with
a sodium lamp. Nuclear magnetic resonance spectra were recorded
on a Bruker Avance III 400 NMRor Bruker Avance 600 spectrometer
at 298 K. Chemical shifts (d) are reported in parts per million (ppm)
with respect to internal tetramethylsilane (TMS) in CDCl3 and re-
sidual HOD signal in D2O. NMR signal assignments were made with
the aid of COSYand HSQC experiments. High resolution ESI MS datawere obtained using a Waters Synapt G2 mass spectrometer; data
for multiply charged species were deconvoluted using the Mass X3
program. Infra-red spectra were obtained on a PerkineElmer FTIR
Spectrum BX instrument equipped with MIRacle single reﬂection
horizontal accessory.
4.1. 2,3,4-Tri-O-benzoyl-6-O-(prop-2-ynyl)-1-O-tri-
chloroacetimidoyl-a-D-galactopyranose (4)
Benzoyl chloride (25 mL, 215 mmol) was added dropwise to
a stirred solutionof 6-O-propargyl galactose (1)31 (9.7 g, 43mmol) in
pyridine (95 mL) at 0 C, the mixture was stirred for 1 h at room
temperature and ice-cold water (100 mL) was carefully added. The
productwas extractedwith CH2Cl2 (3125mL), the organic extracts
were combined and washed with ice-cold 1M HCl (3100 mL),
saturated aqueous NaHCO3 solution (4100 mL), dried (MgSO4),
ﬁltered and concentrated under reduced pressure. The obtained
residue was puriﬁed by ﬂash column chromatography (toluene/
EtOAc, 7:3) to give compound 2 (21.9 g, 81%, mixture of a/b-anom-
ers) as a colourless solid. Benzoate 2 (6.6 g,104mmol)was dissolved
in anhydrous THF (70mL), 7 N NH3 inmethanol (23mL) was added,
the solution was stirred for 26 h at room temperature and the sol-
ventwas removedunder reducedpressure. The residuewas puriﬁed
by ﬂash column chromatography (hexane/EtOAc, 7:3) to give
hemiacetal 3 (3.5 g, 64%). Compound 3 (2.8 g, 5.2 mmol) and tri-
chloroacetonitrile (1.9 g, 13.0 mmol) were dissolved in anhydrous
CH2Cl2 (10 mL), the solution was cooled to 0 C, stirred for 2 h and
concentrated under reduced pressure. The residue was puriﬁed by
ﬂash column chromatography (hexane/EtOAc, 7:3) to afford tri-
chloroacetimidate 4 (2.9 g, 99%) as a colourless syrup. Rf 0.55
(hexane/EtOAc, 7:3); [a]D þ1.2 (c 0.6, CHCl3); dH (400 MHz, CDCl3)
8.61 (1H, s, NH), 8.09e8.07 (2H, m, Ph), 7.96e7.93 (2H, m, Ph),
7.81e7.79 (2H, m, Ph), 7.63 (1H, m, Ph), 7.52e7.24 (8H, m, Ph), 6.88
(1H, d, J1,2¼3.6 Hz, H-1), 6.08 (1H, dd, J3,4¼3.4 Hz, J4,5¼1.3 Hz, H-4),
6.04 (1H, dd, J3,4¼3.4 Hz, J2,3¼10.6 Hz, H-3), 5.92 (1H, dd, J1,2¼3.6 Hz,
J2,3¼10.6 Hz, H-2), 4.68 (1H, m, H-5), 4.12 (2H, m, CH2C^CH), 3.75
(2H, d, J¼6.2 Hz, H-6a, H-6b), 2.24 (1H, t, J¼2.3 Hz, CH2C^CH); dC
(100.6 MHz, CDCl3) 165.7e165.4, 133.6e133.2, 129.9e128.3, 93.9,
75.3, 70.3, 68.6, 68.1, 67.5, 67.1, 58.7; HRMS (ESI) m/z calcd for
C32H26Cl3NO9Naþ ([MþNa]þ): 696.0571, found: 696.0565.
4.2. 2-(2-(2-Chloroethoxy)ethoxy)ethyl 6-O-(prop-2-ynyl)-
2,3,4-tri-O-benzoyl-b-D-galactopyranoside (5)
To a solution of imidate 4 (2.9 g, 5.2 mmol) and 2-(2-(2-
chloroethoxy)ethoxy)ethanol (730 mg, 4.3 mmol) in anhydrous
CH2Cl2 (50 mL) containing 4 A mol. sieves TMSOTf (90 mL,
0.5 mmol) was gradually added at30 C, the reaction mixture was
allowed to warm to room temperature and stirred for 3 h. The re-
actionwas quenched by addition of Et3N (1.0 mL) and concentrated
under reduced pressure. The residue was puriﬁed by ﬂash chro-
matography (EtOAc/hexane, 7:3) to give compound 5 (2.7 g, 85%) as
a colourless solid. Rf 0.17 (EtOAc/hexane, 7:3); [a]D þ0.9 (c 0.7,
CHCl3); IR (neat) 2877, 2360, 1725, 1601, 1584, 1451, 1260, 1094,
750 cm1; dH (400 MHz, CDCl3) 8.09e8.07 (2H, m, Ph), 7.98e7.96
(2H, m, Ph), 7.79e7.77 (2H, m, Ph), 7.61 (1H, m, Ph), 7.53e7.36 (8H,
m, Ph), 5.90 (1H, dd, J3,4¼3.5 Hz, J4,5¼1.0 Hz, H-4), 5.75 (1H, dd,
J1,2¼8.0 Hz; J2,3¼10.5 Hz, H-2), 5.56 (1H, dd, J3,4¼3.5 Hz;
J2,3¼10.5 Hz, H-3), 4.90 (1H, d, J1,2¼8.0 Hz, H-1), 4.19e4.12 (3H, m,
H-5, CH2C^CH), 4.11e4.04 (1H, m, GalOCH2), 3.87e3.81 (1H, m,
GalOCH2), 3.76 (2H, m, H-6a, H-6b), 3.69e3.60 (4H, m, CH2),
3.59e3.53 (2H, m, CH2Cl2), 3.51e3.47 (2H, m, CH2), 3.44e3.38 (2H,
m, CH2), 2.30 (1H, t, J¼2.3 Hz, CH2C^CH); dC (100.6 MHz, CDCl3)
d 165.6e165.2,133.4e133.2,130.0e128.3,101.7, 79.1, 75.0, 72.7, 71.9,
71.3, 70.7, 70.5, 70.4, 69.9, 69.5, 68.5, 67.8, 58.7, 42.7; HRMS (EI)m/z
calcd for C36H37ClO11Naþ ([MþNa]þ): 703.1922, found: 703.1917.
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2,3,4-tri-O-benzoyl-b-D-galactopyranoside (6)
To a solution of b-galactoside 5 (5.2 g, 7.6 mmol) in DMF (50 mL)
NaN3 (2.5 g, 38.0 mmol) and NaI (1.1 g, 8.0 mmol) were added and
the reaction mixture was stirred at 70 C for 28 h. The reaction
mixture was diluted with water (20 mL) and extracted with CH2Cl2
(330 mL). The resulting organic extracts were dried (MgSO4), and
concentrated under reduced pressure to give compound 6 (5.0 g,
97%) as a colourless syrup. Rf 0.17 (hexane/EtOAc, 7:3); [a]D þ0.9 (c
0.7, CHCl3); IR (neat) 2874, 2359, 2107, 1724, 1601, 1584, 1451, 1259,
1094, 752 cm1; dH (400 MHz, CDCl3) 8.09e8.07 (2H, m, Ph),
7.98e7.96 (2H, m, Ph), 7.79e7.77 (2H, m, Ph), 7.61 (1H, m, Ph),
7.53e7.36 (8H, m, Ph), 5.90 (1H, dd, J3,4¼3.5 Hz, J4,5¼1.0 Hz, H-4),
5.75 (1H, dd, J1,2¼8.0 Hz; J2,3¼10.5 Hz, H-2), 5.56 (1H, dd,
J3,4¼3.5 Hz; J2,3¼10.5 Hz, H-3), 4.90 (1H, d, J1,2¼8.0 Hz, H-1),
4.19e4.12 (3H, m, H-5, CH2C^CH), 4.11e4.04 (1H, m, GalOCH2),
3.87e3.81 (1H, m, GalOCH2), 3.76 (2H, m, H-6a, H-6b), 3.69e3.59
(2H, m, CH2), 3.57e3.52 (2H, m, CH2), 3.52e3.46 (2H, m, CH2),
3.44e3.37 (2H, m, CH2), 3.51e3.29 (2H, m, CH2N3), 2.30 (1H, t,
J¼2.3 Hz, CH2C^CH); dC (100.6 MHz, CDCl3) 165.6e165.2,
133.4e133.2, 130.0e128.3, 101.5, 79.1, 75.0, 72.7, 71.9, 71.3, 70.7,
70.5, 70.4, 69.95, 69.9, 69.5, 68.5, 67.8, 58.7, 50.6; HRMS (ESI) m/z
calcd for C36H37N3O11Naþ ([MþNa]þ): 710.2326, found: 710.2320.
4.4. 2-(2-(2-Azidoethoxy)ethoxy)ethyl 6-O-(prop-2-ynyl)-b-D-
galactopyranoside (7)
A solution of compound 6 (2.4 g, 3.48 mmol) in absolute MeOH
(20 mL) was treated with 0.5 M NaOMe in MeOH (2.7 mL,
1.39 mmol), the solution was kept at room temperature for 1 h,
neutralized with dry ice, concentrated under reduced pressure and
puriﬁed by ﬂash chromatography (CH2Cl2/MeOH, 9:1) to give
compound 7 (1.2 g, 91%) as a colourless syrup. [a]D 1.6 (c 1.3,
MeOH); dH (600 MHz, Methanol-d4) 4.16 (1H, d, J1,2¼7.6 Hz, H-1),
4.11 (2H, d, J¼2.4 Hz, CH2C^CH), 3.94e3.84 (1H, m, H-6a), 3.69 (1H,
dd, J3,4¼3.4 Hz, J4,5¼1.1Hz,H-4), 3.67e3.54 (12H,m,H-5,H-6b, CH2),
3.43 (1H, dd, J1,2¼7.6 Hz, J2,3¼9.7 Hz, H-2), 3.37 (1H, dd, J2,3¼9.7 Hz,
J3,4¼3.4 Hz, H-3), 3.28 (2H, t, J¼5.0 Hz, CH2N3), 2.76 (1H, t, J¼2.4 Hz,
CH2C^CH); dC (100.6 MHz, D2O) 105.0, 80.6, 76.0, 75.0, 74.7, 72.5,
71.6 (2C), 71.4, 71.1, 70.4, 70.3, 69.7, 59.3, 51.8; HRMS (ESI)m/z calcd
for C15H25N3O8Naþ ([MþNa]þ): 398.1539, found: 398.1534.
4.5. Cu(I)-catalysed oligomerisation of monomer 7
A solution of azido-alkyne monomer 7 (100 mg, 0.3 mmol)
containing Cu turnings (260 mg, 4.1 mmol) and CuSO4 (11 mg,
0.1 mmol) in DMF (0.27 mL) was placed into a sealed microwave
tube. The tube was either submitted to microwave irradiation at
110 C at 50 W magnetron power (Method A) or stirred at room
temperature for 2 days (Method B). The reaction progress was fol-
lowed by the TLC (CH3CN/EtOAc/iPrOH/H2O, 85:20:50:50) taking
samples at 15 min intervals (Method A) or 24 h intervals (Method B).
After completion the reaction mixtures were separated from Cu
turnings and the solvent was removed by repeated evaporation
with toluene under reduced pressure. The residues were re-dis-
solved in water and subjected to puriﬁcation using HPLC on Phe-
nomenex Luna C-18 column (10250 mm). HPLC method included
linear gradient from 0% to 35% in 50 min of MeCN in 0.1% aqueous
CF3CO2H at 1 mL/min ﬂow rate. Peaks were detected by a CAD and
collected as individual compounds or mixtures of oligomers, which
were identiﬁed using 1H NMR and/or HRMS.
4.5.1. Cyclic monomer 8. HPLC retention time 16.3 min; yield
9.0 mg (9.0%) (Method A), 6.7 mg (6.7%) (Method B); dH (400 MHz,
D2O) 8.15 (1H, s, CH triazole), 4.93 (1H, d, J¼13.4 Hz, CH2a-triazole),4.71e4.61 (3H, m, CH2b-triazole, CH2N), 4.38 (1H, d, J1,2¼7.9 Hz, H-
1), 4.02e3.94 (3H, m, OCH2CH2N, H-6a), 3.91 (1H, d, J3,4¼3.5 Hz, H-
4), 3.90e3.66 (10H, m, CH2, H-5, H-6b), 3.64 (1H, dd, J2,3¼9.7 Hz;
J3,4¼3.5 Hz, H-3), 3.50 (1H, dd, J1,2¼7.9 Hz; J2,3¼9.7 Hz, H-2); dC
(100.6 MHz, D2O) 143.6, 126.2, 102.2, 74.2, 72.7, 70.6, 69.6, 69.4,
69.4, 69.1, 68.9, 68.5, 62.4, 49.7; HRMS (EI) m/z calcd for
C15H26N3O8þ [MþH]þ: 376.1714, found 376.1710.
4.5.2. Cyclic dimer 9. HPLC retention time 21.3 min; yield 3.0 mg
(3.0%) (Method A), 2.2 mg (2.2%) (Method B); dH (400MHz, D2O) 8.12
(2H, s, CH triazole), 4.74 (4H, m, CH2-triazole), 4.65 (4H, m, CH2N),
4.38 (2H, d, J1,2¼7.9 Hz, H-1), 4.02e3.92 (6H, m, OCH2CH2N, H-6a),
3.91 (2H, d, J3,4¼3.6 Hz, H-4), 3.86e3.70 (8H, m, CH2, H-5, H-6b),
3.69e3.57 (14H, m, CH2, H-3), 3.53 (2H, dd, J1,2¼7.9 Hz, J2,3¼9.9 Hz,
H-2); dC (100.6 MHz, D2O) 143.7, 125.6, 102.8, 73.5, 72.6, 70.6, 69.6
(2C), 69.4, 68.9, 68.7, 68.6, 63.4, 50.1; HRMS (ESI) m/z calcd for
C30H51N6O16 ([MþH]þ): 751.3357, found: 751.3334.
4.5.3. Cyclic trimer 10. HPLC retention time 23.9 min; yield 1.6 mg
(1.6%) (Method A), 1.0 mg (1.0%) (Method B); dH (400 MHz, D2O)
8.10 (3H, s, CH triazole), 4.72 (6H, m, CH2-triazole), 4.63 (6H, m,
CH2N), 4.39 (3H, d, J1,2¼7.8 Hz, H-1), 4.00e3.93 (9H, m, OCH2CH2N,
H-6a), 3.90 (3H, d, J3,4¼3.4 Hz, H-4), 3.85e3.73 (12H, m, CH2, H-5,
H-6b), 3.70e3.58 (21H, m, CH2, H-3), 3.53 (3H, dd, J1,2¼7.9 Hz,
J2,3¼9.9 Hz, H-2); dC (100.6 MHz, D2O) 143.8, 125.5, 102.8,
73.5, 72.6, 70.6, 69.7, 69.6 (2C), 69.4, 68.9, 68.7, 63.4, 50.0; HRMS
(ESI) m/z calcd for C45H76N9O24 ([MþH]þ): 1126.4998, found:
1126.4961.
4.5.4. Cyclic tetramer 11. HPLC retention time 25.5 min; yield
1.1 mg (1.1%) (Method A), 0.8 mg (0.8%) (Method B); dH (400 MHz,
D2O) 8.10 (4H, s, CH triazole), 4.72 (8H, m, CH2-triazole), 4.63 (8H,
m, CH2N), 4.39 (4H, d, J1,2¼7.8 Hz, H-1), 4.00e3.93 (12H, m,
OCH2CH2N, H-6a), 3.90 (4H, d, J3,4¼3.4 Hz, H-4), 3.85e3.73 (16H, m,
CH2, H-5, H-6b), 3.70e3.58 (28H, m, CH2, H-3), 3.53 (4H, dd,
J1,2¼7.9 Hz, J2,3¼9.9 Hz, H-2); dC (100.6 MHz, D2O) 143.8, 125.5,
102.8, 73.5, 72.6, 70.6, 69.7, 69.6, 69.5, 69.4, 68.9, 68.7, 63.4, 50.0;
HRMS (ESI) m/z calcd for C60H101N12O32 ([MþH]þ): 1501.664,
found: 1501.6511.
4.5.5. Cyclic pentamer 12. HPLC retention time 26.5 min; yield
1.3 mg (1.3%) (Method A), 0.6 mg (0.6%) (Method B); dH (400 MHz,
D2O) 8.10 (5H, s, CH triazole), 4.71 (10H, m, CH2-triazole), 4.63 (10H,
m, CH2N), 4.39 (5H, d, J1,2¼7.9 Hz, H-1), 4.01e3.94 (15H, m,
OCH2CH2N, H-6a), 3.90 (5H, d, J3,4¼3.4 Hz, H-4), 3.85e3.73 (20H, m,
CH2, H-5, H-6b), 3.70e3.58 (35H, m, CH2, H-3), 3.53 (5H, dd,
J1,2¼7.9 Hz, J2,3¼9.9 Hz, H-2); dC (100.6 MHz, D2O) 143.8, 125.5,
102.8, 73.5, 72.6, 70.6, 69.6, 69.6, 69.5, 69.4, 68.9, 68.7 (2C), 63.4,
50.0; HRMS (ESI)m/z calcd for C75H126N15O40 ([MþH]þ): 1876.8281,
found: 1876.8248.
4.5.6. Cyclic hexamer 13. HPLC retention time 27.2 min; yield
0.5 mg (0.5%) (Method B); dH (400 MHz, D2O) 8.11 (6H, s, CH tri-
azole), 4.72 (12H, m, CH2-triazole), 4.67e4.62 (12H, m, CH2N), 4.39
(6H, d, J1,2¼7.8 Hz, H-1), 4.01e3.96 (18H, m, OCH2CH2N, H-6a), 3.90
(6H, d, J3,4¼2.8 Hz, H-4), 3.87e3.71 (24H, m, CH2, H-5, H-6b),
3.70e3.59 (42H, m, CH2, H-3), 3.53 (6H, dd, J1,2¼7.9 Hz, J2,3¼9.8 Hz,
H-2); dC (100.6 MHz, D2O) 102.8, 73.4, 72.5, 70.6, 69.5, 69.3, 68.8,
68.7, 63.4, 50.0; HRMS (ESI)m/z calcd for C90H151N18O48 ([MþH]þ):
2251.9923, found: 2251.9792.
4.5.7. Cyclic oligomers (DP>6). HPLC retention time 28e30 min;
yield 13.7 mg (13.7%) (Method A), 6.0 mg (6.0%) (Method B).
4.5.8. Linear oligomers. HPLC retention time 32.0 min; yield
25.8 mg (25.8%) (Method A), 35.7 mg (35.7%) (Method B); HRMS
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1501.6640; 1876.8281; 2251.9923, found: 376.1708; 751.3351;
1126.4985; 1501.6631; 1876.8273; 2251.9897.
4.6. Uncatalysed oligomerisation of monomer 7
A solution of compound 7 (100 mg, 0.3 mmol) was placed into
a sealed microwave tube. The reaction mixture was submitted to
microwave irradiation at 110 C at 50Wmagnetron power (Method
C). The reaction progress was followed by TLC (CH3CN/EtOAc/
iPrOH/H2O, 85:20:50:50) taking samples at 15 min intervals
(Method C). After 30 min the solvent was removed by repeated
evaporation with toluene under reduced pressure. The residues
were redissolved in water and subjected to puriﬁcation using HPLC
on Phenomenex Luna C-18 column (10250 mm). HPLC method
included linear gradient from 0% to 35% in 50 min of MeCN in 0.1%
aqueous CF3CO2H. Peaks were detected by a CAD detector and
collected as individual compounds or mixtures of oligomers, which
were identiﬁed using 1H NMR and/or HRMS (ESI).
4.6.1. Linear dimer 14. HPLC retention time 32.0 min; yield 1.2 mg
(1.2%); dH (400 MHz, D2O) 8.02 (s, 1H), 4.60e4.52 (2H, m, CH2-tri-
azole), 4.36e4.27 (2H, m, H-1, H-10), 4.23e4.14 (2H, m, CH2C^CH),
3.98e3.87 (4H, m, OCH2CH2N), 3.84e3.81 (2H, m, H-4), 3.78e3.52
(26H, m, CH2, H-6, H0, H5, H-3), 3.47e3.41 (4H, m, H-2, CH2N3); dC
(100.6 MHz, D2O) 102.7, 76.9, 73.4, 72.5, 70.5, 68.7, 68.5, 63.3, 58.1,
50.0, 49.9.
4.6.2. Cyclic monomer 19. HPLC retention time 14.9 min; yield
8.7 mg (8.7%); dH (400 MHz, D2O) 7.88 (1H, s, CH triazole),
4.92e4.83 (2H, m, CH2-triazole), 4.72e4.56 (2H, m, CH2N), 4.42 (1H,
d, J1,2¼7.9 Hz, H-1), 4.06e4.02 (2H, m, OCH2CH2N), 3.97e3.82 (6H,
m, CH2, H-4, H-5,H-6), 3.74e3.57 (7H, m, CH2, H-3), 3.53 (1H, dd,
J1,2¼7.9 Hz; J2,3¼9.9 Hz, H-2); dC (100.6MHz, D2O) 140.5,102.2, 74.4,
72.7, 71.1, 70.6, 70.3, 69.7, 69.5, 69.3, 68.8, 61.2, 48.5; HRMS (ESI)m/z
Calcd for C15H26N3O8 ([MþH]þ): 376.1751, found: 376.1701.
4.6.3. Linear dimer 20. HPLC retention time 32.0 min; yield 1.5 mg
(1.5%); dH (400 MHz, D2O) 7.77 (1H, s, CH triazole), 4.60e4.54 (2H,
m, CH2N), 4.35e4.29 (2H, m, H-1, H-10), 4.23e4.14 (2H, m,
CH2C^CH), 3.97e3.88 (4H, m, OCH2CH2N), 3.84e3.81 (2H, m, H-
4),3.78e3.52 (26H, m, CH2, H-6, H-5, H-3), 3.47e3.41 (4H, m, H-2,
CH2N3); dC (100.6 MHz, D2O) 102.7, 73.1, 72.4, 70.6, 68.7, 68.6, 60.3,
58.1, 50.0, 48.1.
4.7. trans-Sialidase-mediation sialylation of triazole-linked
pseudo-galactooligomers
To a solution of fetuin41 as a donor substrate (25 mL, 3 mM in
0.1 mM phosphate buffer pH 7.0) and triazole-linked acceptor
substrates 8e10 and 19 (25 mL, 1 mM in 0.1 mM phosphate buffer
pH 7.0) was added TcTS enzyme (25 mL). Themixturewas incubated
at 28 C for 5 days when additional 25 mL aliquots of TcTS enzyme
and fetuin were added; after a further 2 days additional 25 mL ali-
quot of fetuin was added. Reaction progress was followed by TLC
(CH3CN/EtOAc/iPrOH/H2O, 85:20:50:50). The protein was pre-
cipitated by heating the mixture at 100 C for 1 min and the
denatured enzymes were removed by centrifugation (14,000 rpm,
5 min). The supernatant was transferred to a new Eppendorf tube,
concentrated by freeze drying and submitted to HRMS analysis.
4.8. Macrophage invasion assays
Compounds used in preliminary macrophage invasion assays
included a series of mixed 1,4/1,5- triazole-linked cyclic compounds
C2, C3, C4, C5, C6, and C7 and a mixture of linear 1,4/1,5-triazole-linked oligomers generated by Method C (Section 4.6). Trypano-
soma cruzi Y strain was cultivated in the LLC-MK2 host cells, as
described elsewhere.42
4.8.1. Preparation of macrophages. Macrophages derived from
bone marrow (BMMOs) were obtained as described previously.43
Brieﬂy, total bone marrow cells were cultured in RPMI 1640 me-
dium (SigmaeAldrich), supplemented with 10% Fetal Bovine Se-
rum (Cutilab) and 30% L-929 cell-conditioned media at 37 C
under 5% CO2 atmosphere. On the seventh day of culture BMMOs
were harvested and plated in 96 or 24 well microplates (at 5105
cells/mL).
4.8.2. Preparation of trypomastigotes. Trypomastigote form Trypa-
nosoma cruzi Y strain (1.5106 cells/mL) was added into wells
containing BMMOs in two different ways: (Treatment 1) trypo-
mastigotes and triazole-linked compounds at a ﬁnal concentration
of 250 mM were plated at the same time; and (Treatment 2) try-
pomastigotes and triazole-linked compounds at a ﬁnal concentra-
tion of 250 mM were ﬁrst pre-incubated for 1 h, then the parasites
were washed to remove free compound and were plated to the
wells containing BMMOs. In both methods the trypomastigotes
were maintained for 2 h in contact with BMMOs. The parasites that
had not invaded macrophages were removed by serial washing
after the 2 h incubation.
4.8.3. Analysis of released trypomastigotes. After six days in-
cubation, free trypomastigotes that had escaped frommacrophages
were counted in a Neubauer chamber and results are expressed as
a percentage inhibition with respect to trypomastigotes released
from infected cells that had not been treated with triazole-linked
compounds.
4.8.4. Analysis of amastigotes inside BMMOs. Macrophages infected
with trypomastigotes as described above (Treatment 1) were
maintained in culture for four days, during, which time the para-
sites differentiated into amastigote forms. The infected macro-
phages were ﬁxed with methanol, stained with Giemsa and
analysed using Leica DMI 4000B microscope. The results are
expressed as an average number of amastigotes per macrophage.Acknowledgements
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